S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Olympic track uniforms spark online debate about who designed them and why they're so skimpy

Chimerix (CMRX) Stock Price, News & Analysis

$0.96
-0.03 (-3.03%)
(As of 04/12/2024 ET)
Today's Range
$0.95
$1.02
50-Day Range
$0.91
$1.26
52-Week Range
$0.88
$1.57
Volume
235,362 shs
Average Volume
419,239 shs
Market Capitalization
$85.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Chimerix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
732.7% Upside
$8.00 Price Target
Short Interest
Healthy
1.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.49
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$6,598 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.77) to ($0.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.26 out of 5 stars

Medical Sector

139th out of 927 stocks

Pharmaceutical Preparations Industry

51st out of 435 stocks

CMRX stock logo

About Chimerix Stock (NASDAQ:CMRX)

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

CMRX Stock Price History

CMRX Stock News Headlines

CMRX Apr 2024 2.000 call
CMRX Apr 2024 1.000 put
How to Get Rich From A Miracle Drug Touted by Elon Musk
When it comes to the $15.7 trillion build out of A.I., we haven't even gotten started, folks. And that spells opportunity in 2024. Last year, a group of stocks dubbed "The Magnificent Seven" soared as investors piled into these A.I. leaders, sending shares of the group an average of 111%. Compare that to the S&P 500's 24% gain... it's no contest.
How to Get Rich From A Miracle Drug Touted by Elon Musk
When it comes to the $15.7 trillion build out of A.I., we haven't even gotten started, folks. And that spells opportunity in 2024. Last year, a group of stocks dubbed "The Magnificent Seven" soared as investors piled into these A.I. leaders, sending shares of the group an average of 111%. Compare that to the S&P 500's 24% gain... it's no contest.
Preview: Chimerix's Earnings
Chimerix Appoints Lisa Decker to Board of Directors
Positive Signs As Multiple Insiders Buy Chimerix Stock
Chimerix Appoints Michelle LaSpaluto As CFO
See More Headlines
Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/13/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CMRX
Employees
72
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+732.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-82,100,000.00
Net Margins
-25,337.96%
Pretax Margin
-25,337.96%

Debt

Sales & Book Value

Annual Sales
$320,000.00
Book Value
$2.17 per share

Miscellaneous

Free Float
80,289,000
Market Cap
$85.70 million
Optionable
Optionable
Beta
1.15

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Michael T. Andriole M.B.A. (Age 51)
    CEO, President & Director
    Comp: $592.95k
  • Dr. Allen S. Melemed M.B.A. (Age 60)
    M.D., Chief Medical Officer
    Comp: $605.29k
  • Ms. Michelle LaSpaluto (Age 49)
    Chief Financial Officer
  • Mr. Thomas J. Riga (Age 48)
    Chief Operating & Commercial Officer
  • Mr. David Jakeman CPA (Age 46)
    VP of Accounting & Finance
  • Dr. Joshua E. Allen Ph.D.
    Chief Technology Officer
  • Dr. Michael A. Alrutz J.D. (Age 54)
    Ph.D., Senior VP, General Counsel & Corporate Secretary
    Comp: $619.5k
  • Dr. Roy W. Ware MBA
    Ph.D., Chief Manufacturing Technology Officer
  • Dr. Pablo Lee M.D.
    Head of Medical Affairs

CMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Chimerix stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings
or view top-rated stocks.

What is Chimerix's stock price target for 2024?

3 Wall Street analysts have issued 1 year price objectives for Chimerix's shares. Their CMRX share price targets range from $6.00 to $11.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 732.7% from the stock's current price.
View analysts price targets for CMRX
or view top-rated stocks among Wall Street analysts.

How have CMRX shares performed in 2024?

Chimerix's stock was trading at $0.9625 on January 1st, 2024. Since then, CMRX shares have decreased by 0.2% and is now trading at $0.9607.
View the best growth stocks for 2024 here
.

When is Chimerix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CMRX earnings forecast
.

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) posted its quarterly earnings data on Thursday, February, 29th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.03. Chimerix had a negative net margin of 25,337.96% and a negative trailing twelve-month return on equity of 37.93%.

What other stocks do shareholders of Chimerix own?
How do I buy shares of Chimerix?

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMRX) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners